Rene Tavernier

Rene Tavernier

Auto-generated profile, based on publicly available information

Rene Tavernier

Cardiology Department, AZ Sint-Jan Brugge , Ruddershove 10, Bruges 8000

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2021 in EP Europace
Verified
Journal Article
Closed access
PHPhilipp Halbfass
Philipp Halbfass
JWJean-Yves Wielandts
Jean-Yves Wielandts
SKSébastien Knecht
Sébastien Knecht
JWJean-Benoît Le Polain de Waroux
Jean-Benoît Le Polain de Waroux
RTRené Tavernier
René Tavernier
TDThomas Deneke
Thomas Deneke
Aims: Very high-power short-duration (vHPSD) via temperature-controlled ablation (TCA) is a new modality to perform radiofrequency pulmonary vein isolation (PVI), conceivably at the cost of a narrower safety margin towards the oesophagus. In this two-centre trial, we aimed to determine the safety of vHPSD-based PVI with specific emphasis on silent oesophageal injury. Methods and results: Ninety consecutive patients with atrial fibrillation (AF) underwent vHPSD-PVI (90 W, 3–4 s, TCA) using the QDOT MICRO catheter, in conjunction with the nGEN (Bad Neustadt, n = 45) or nMARQ generator (Bruges, n = 45). All patients underwent post-ablation oesophageal endoscopy. Procedural parameters and complications were recorded. A subgroup of 21 patients from Bad Neustadt underwent cerebral magnetic resonance imaging (cMRI) to detect silent cerebral events (SCEs). Mean age was 67 ± 9 years, 59% patients were male, and 66% patients had paroxysmal AF. Pulmonary vein isolation was obtained in all cases after 96 ± 29 min. No steam pop, cardiac tamponade, stroke, or fistula was reported. None of the 90 patients demonstrated oesophageal ulceration (0%). Charring was not observed in the nMARQ cohort (0% vs. 11% in the nGEN group). In 5 out of 21 patients (24%), cMRI demonstrated SCE (exclusively nGEN cohort). Conclusion: Temperature-controlled vHPSD catheter ablation allows straightforward PVI without evidence of oesophageal ulcerations or symptomatic complications. Catheter tip charring and silent cerebral lesions when using the nGEN generator have led to further modification.

1 November 2024 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
MDMattias Duytschaever
Mattias Duytschaever
RARobin Van Den Abeele
Robin Van Den Abeele
NCNiels Carlier
Niels Carlier
ABArthur Santos Bezerra
Arthur Santos Bezerra
BVBjorn Verstraeten
Bjorn Verstraeten
NVNele Vandersickel
Nele Vandersickel
BACKGROUND: Macroreentry stands as the predominant mechanism of typical and atypical flutter. Despite advances in mapping, many aspects of macroreentrant atrial tachycardia remain unsolved. In this translational study, we applied principles of topology to understand the activation patterns, entrainment characteristics, and ablation responses in a large clinical macroreentrant atrial tachycardia database. METHODS: Because the atrium can be topologically seen as a closed sphere with holes, we used a computational fixed spherical mesh model with a finite number of holes to induce and analyze macroreentrant atrial tachycardia. The ensuing insights were used to interpret high-density activation maps, postpacing interval-tachycardia cycle length values (difference between postpacing interval and tachycardia cycle length), and ablation response in 131 cases of typical and atypical flutter (n=106 left atrium, n=25 right atrium). RESULTS: Modeling of macroreentrant atrial tachycardia revealed that reentry on closed surfaces consistently manifests itself as paired rotation and that an odd number of critical boundaries is mathematically impossible. Together with mathematical confirmation by the index theorem, this led to a unifying construct that could explain the number of loops, difference between postpacing interval and tachycardia cycle length values, and ablation outcomes (termination, no change, or prolongation in tachycardia cycle length) in all 131 cases. CONCLUSIONS: Combining topology with the index theorem offers a novel and cohesive framework for understanding and managing typical and atypical flutter.

26 February 2025 in European Heart Journal
Verified
Journal Article
Open access
PDPhilippe Debonnaire
Philippe Debonnaire
KDKarl Dujardin
Karl Dujardin
NVNicolas Verheyen
Nicolas Verheyen
APAnne-Catherine Pouleur
Anne-Catherine Pouleur
SDSteven Droogmans
Steven Droogmans
RTRené Tavernier
René Tavernier
Background and Aims: In real-world, wild-type transthyretin cardiomyopathy is increasingly diagnosed in patients ≥ 80 years old (octogenarians), although being underrepresented in randomized clinical trials. Specific data on natural course and outcome under tafamidis treatment in octogenarians are therefore scarce. The impact of tafamidis treatment on mortality in real-world wild-type transthyretin cardiomyopathy octogenarians was studied. Methods: An international, multicentre cohort study of 710 consecutive wild-type transthyretin cardiomyopathy patients with mean follow-up of 2.2 ± 1.8 years for all-cause mortality endpoint was performed. Results: The cohort consisted of 58.5% (415/710) octogenarians (85 ± 4 years, 74.2% male). Before tafamidis availability, natural course in octogenarians (148/257) vs. non-octogenarians (109/257) was poor, with 16% 1-year and 71% 5-year mortality vs. 8% and 47%, respectively (P < .001). Since tafamidis availability, 70.1% (253/361) octogenarians were initiated on tafamidis vs. 83.7% (231/276) non-octogenarians (P < .001). Tafamidis discontinuation was similar (octogenarians 10.3% and non-octogenarians 7.4%; P = .260). Overall tafamidis treated vs. untreated octogenarians had better unadjusted survival (P < .001), with 5% 1-year and 24% 3-year mortality. Tafamidis treatment associated with lower mortality after propensity score matching on baseline variables, including age, National Amyloidosis Centre stage, and New York Heart Association class in on average 394 subjects [hazard ratio (HR) = 0.53, 95% confidence interval (CI) 0.34–0.84, P = .007], also in octogenarians (HR = 0.57, 95% CI 0.33–1.01, P = .053). Neither age at diagnosis (P = .217) nor at treatment initiation (P = .154) interacted with tafamidis mortality benefit. Octogenarians had poorer survival despite tafamidis, when initiated at ≥90 years (HR = 3.3, 95% CI 1.10–9.53, P = .033) and National Amyloidosis Centre Stage ≥3 (HR = 2.4, 95% CI 0.87–6.46, P = .090). Conclusions: Real-world tafamidis treatment improves survival without age affecting treatment efficacy, although mortality remains considerable in octogenarians.

1 October 2024 in EP Europace
Verified
Journal Article
Open access
PDF file
MSMaarten A J De Smet
Maarten A J De Smet
CFClara François
Clara François
BBBenjamin De Becker
Benjamin De Becker
RTRene Tavernier
Rene Tavernier
JWJean-Benoît le Polain de Waroux
Jean-Benoît le Polain de Waroux
MDMattias Duytschaever
Mattias Duytschaever
Pulmonary vein isolation (PVI) is an established cornerstone of rhythm management in patients with atrial fibrillation (AF).1,2 Before pulsed field ablation (PFA), PVI lesions were solely created by thermal radiofrequency (RF), cryo, or laser energy. Pulsed field ablation, resulting in irreversible electroporation of cell membranes to which cardiac muscle is especially sensible, is the first non-thermal energy that provides effective PVI with good durability, including non-inferiority when compared with RF.2,3

25 June 2020 in Journal of Medical Internet Research
Verified
Journal Article
Open access
PVPieter Vandekerckhove
Pieter Vandekerckhove
YVYves Vandekerckhove
Yves Vandekerckhove
RTRene Tavernier
Rene Tavernier
KJKelly De Jaegher
Kelly De Jaegher
MMMarleen de Mul
Marleen de Mul
During the coronavirus disease (COVID-19) pandemic, cardiologists have attempted to minimize risks to their patients by using telehealth to provide continuing care. Rapid implementation of video consultations in outpatient clinics for patients with heart disease can be challenging. We employed a design thinking tool called a customer journey to explore challenges and opportunities when using video communication software in the cardiology department of a regional hospital. Interviews were conducted with 5 patients with implanted devices, a nurse, an information technology manager and two cardiologists. Three lessons were identified based on these challenges and opportunities. Attention should be given to the ease of use of the technology, the meeting features, and the establishment of the connection between the cardiologist and the patient. Further, facilitating the role of an assistant (or virtual assistant) with the video consultation software who can manage the telehealth process may improve the success of video consultations. Employing design thinking to implement video consultations in cardiology and to further implement telehealth is crucial to build a resilient health care system that can address urgent needs beyond the COVID-19 pandemic.

5 February 2015 in EP Europace
Verified
Journal Article
Open access
PDF file
BBBenjamin Berte
Benjamin Berte
MDMattias Duytschaever
Mattias Duytschaever
JEJuliana Elices
Juliana Elices
VKVikas Kataria
Vikas Kataria
LTLiesbeth Timmers
Liesbeth Timmers
RTRene Tavernier
Rene Tavernier
To assess in young athletes (i) the variability in the percentage of abnormal electrocardiograms (ECGs) using different criteria and (ii) the variability in ECG interpretation among cardiologists and sport physicians. Electrocardiograms of 138 athletes were categorized by seven cardiologists according to the original European Society of Cardiology (ESC) criteria by Corrado (C), subsequently modified by Uberoi (U), Marek (M), and the Seattle criteria (S); seven sports physicians only used S criteria. The percentage of abnormal ECGs for each physician was calculated and the percentage of complete agreement was assessed. For cardiologists, the median percentage of abnormal ECGs was 14% [interquartile range (IQR) 12.5–20%] for C, 11% (IQR 9.5–12.5%) for U [not significant (NS) compared with C], 11% (IQR 10–13%) for M (NS compared with C), and 7% (IQR 5–8%) for S (P < 0.005 compared with C); complete agreement in interpretation was 64.5% for C, 76% for U (P < 0.05 compared with C), 74% for M (NS compared with C), and 84% for S (P < 0.0005 compared with C). Sport physicians classified a median of 7% (IQR 7–11%) of ECGs as abnormal by S (P = NS compared with cardiologists using S); complete agreement was 72% (P < 0.05 compared with cardiologists using S). Seattle criteria reduced the number of abnormal ECGs in athletes and increased agreement in classification. However, variability in ECG interpretation by cardiologists and sport physicians remains high and is a limitation for ECG-based screening programs.